Week 14: Baucus Releases Bill, HHS Announces New Grants

WASHINGTON (MedPage Today) — This week, the long-anticipated healthcare reform bill made its way out of the Senate Finance Committee, and the administration debuted two pilot programs — one testing the medical home, the other tort reform.

Millennium’s sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple [...]

Forest Laboratories Presents Analysis Of Two Positive Pivotal Phase III Studies Of Ceftaroline For The Treatment Of Community-Acquired Pneumonia (CAP)

Forest Laboratories, Inc (NYSE: FRX) presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III studies of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients.

Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets

Mylan Inc. (NASDAQ: MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.

Professor Shimizu, Winner Of The 2009 Enzyme Engineering Award.

The 2009 Enzyme Engineering Award, presented in the name of Engineering Conferences International and the Genencor division of Danisco A/S, will be awarded to Professor Sakayu Shimizu of Kyoto University. Dr. Shimizu has made extraordinary contributions to both fundamental and applied sciences.

Wellcome Trust And Merck Launch Joint Venture To Develop Affordable Vaccines For Low-Income Countries

The Wellcome Trust and Merck & Co., Inc. have announced the creation of the MSD-Wellcome Trust Hilleman Laboratories, a unique research and development joint venture with a not-for-profit mission to focus on developing affordable vaccines for diseases that commonly affect low-income countries. The joint venture marks the first time a research charity [...]

Abbott Wins Top Honor In Wall Street Journal Technology Innovation Awards

Abbott announced it has been named the overall Gold winner of the 2009 Wall Street Journal Technology Innovation Awards for its Ibis T5000 Biosensor system, which is designed to detect and characterize a broad range of infectious agents in a given sample, including viruses, bacteria and fungi. “Abbott is dedicated to pursuing innovation [...]

Abbott Expands Use Of Sustainable Packaging As Part Of Global Environmental Efforts

Abbott today reported further progress in meeting its goal of a 5 percent reduction in the amount of packaging used in its key products by 2013, part of a multi-faceted effort to minimize its impact on the environment. To achieve this goal, the company has launched, or is in the process of launching, more than [...]

CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5th Annual Ophthalmic Drug Development and Delivery Summit to be held September 21-22, 2009 in San Diego.

PCMA statements on mail-service pharmacies

The Pharmaceutical Care Management Association (PCMA) issued the following statement on a consumer “poll” on mail-service pharmacies released today by the National Community Pharmacists Association (NCPA).